Geron (GERN) Competitors $3.49 -0.17 (-4.64%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GERN vs. RGEN, MDGL, HALO, IONS, ALKS, FOLD, LGND, CLDX, MNKD, and DVAXShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), MannKind (MNKD), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. Geron vs. Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals Celldex Therapeutics MannKind Dynavax Technologies Repligen (NASDAQ:RGEN) and Geron (NASDAQ:GERN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Which has more risk and volatility, RGEN or GERN? Repligen has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RGEN or GERN? 97.6% of Repligen shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 3.1% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor RGEN or GERN? In the previous week, Repligen had 12 more articles in the media than Geron. MarketBeat recorded 22 mentions for Repligen and 10 mentions for Geron. Geron's average media sentiment score of 0.91 beat Repligen's score of 0.62 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 6 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Geron 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RGEN or GERN? Repligen presently has a consensus target price of $185.20, indicating a potential upside of 28.20%. Geron has a consensus target price of $7.15, indicating a potential upside of 104.87%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Geron is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.62Geron 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09 Is RGEN or GERN more profitable? Repligen has a net margin of -3.36% compared to Geron's net margin of -682.48%. Repligen's return on equity of 3.90% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Repligen-3.36% 3.90% 2.72% Geron -682.48%-67.53%-45.46% Which has higher earnings & valuation, RGEN or GERN? Repligen has higher revenue and earnings than Geron. Repligen is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$639.92M12.65$35.60M-$0.37-390.43Geron$29.48M71.56-$184.13M-$0.32-10.91 Does the MarketBeat Community believe in RGEN or GERN? Geron received 84 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 70.03% of users gave Geron an outperform vote while only 67.60% of users gave Repligen an outperform vote. CompanyUnderperformOutperformRepligenOutperform Votes40967.60% Underperform Votes19632.40% GeronOutperform Votes49370.03% Underperform Votes21129.97% SummaryGeron beats Repligen on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-10.9110.5991.3417.19Price / Sales71.56195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book7.595.104.794.78Net Income-$184.13M$151.51M$120.07M$225.60M7 Day Performance-9.59%-2.14%-1.90%-1.24%1 Month Performance-13.18%-3.13%11.43%3.06%1 Year Performance55.80%11.51%30.59%16.50% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron3.8487 of 5 stars$3.49-4.6%$7.15+104.9%+61.6%$2.11B$29.48M-10.91141Short Interest ↓High Trading VolumeRGENRepligen4.0971 of 5 stars$160.24+2.4%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2396 of 5 stars$310.87+2.1%$347.33+11.7%+39.5%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive NewsIONSIonis Pharmaceuticals4.4165 of 5 stars$38.46+5.1%$60.65+57.7%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsALKSAlkermes4.6624 of 5 stars$30.76+0.8%$35.42+15.1%+9.3%$4.98B$1.51B15.652,100Positive NewsFOLDAmicus Therapeutics4.326 of 5 stars$9.90+5.8%$16.88+70.5%-23.7%$2.96B$493.67M-28.71480Analyst DowngradeLGNDLigand Pharmaceuticals4.9831 of 5 stars$123.60+5.7%$147.00+18.9%+65.4%$2.34B$152.42M47.4480Analyst RevisionCLDXCelldex Therapeutics2.6676 of 5 stars$26.43+4.0%$62.25+135.5%-33.5%$1.75B$6.88M-9.89160Analyst ForecastNews CoveragePositive NewsMNKDMannKind3.199 of 5 stars$6.29-3.8%$8.67+37.8%+105.4%$1.73B$198.96M93.43400Analyst UpgradeAnalyst RevisionNews CoverageDVAXDynavax Technologies4.6677 of 5 stars$12.98+0.2%$22.00+69.5%-4.1%$1.71B$260.81M100.00408Positive News Related Companies and Tools Related Companies RGEN Competitors MDGL Competitors HALO Competitors IONS Competitors ALKS Competitors FOLD Competitors LGND Competitors CLDX Competitors MNKD Competitors DVAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GERN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
